Inhibrx Biosciences Q3 2025 Earnings Report

Inhibrx Biosciences EPS Results

• Actual EPS: -$2.28
• Consensus EPS: -$2.94
• Beat/Miss: Beat by +$0.66
• One Year Ago EPS: N/A

Inhibrx Biosciences Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Inhibrx Biosciences Announcement Details

• Quarter: Q3 2025
• Date: 11/13/2025
• Time: Before Market Opens
• Conference Call Date: Thursday, November 13, 2025
• Conference Call Time: 6:00PM ET

Inhibrx, Inc., headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company’s proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need.

The company’s lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration. INBRX-109 is being evaluated in early-stage clinical studies for indications such as chronic wounds and tissue damage. In addition to its ROR2 program, Inhibrx is advancing a pipeline of preclinical assets targeting pathways including Tie2 and neuropilin-2 (NRP2), each selected for their potential to modulate angiogenesis, immune responses or fibrotic processes.

Founded in 2006, Inhibrx completed its initial public offering in 2016 and trades on the Nasdaq under the ticker INBX. The company collaborates with academic research centers and strategic industry partners to accelerate the translation of its engineered proteins from discovery through clinical development. Inhibrx’s leadership team brings together expertise in molecular biology, protein engineering, translational science and regulatory affairs to drive the advancement of its therapeutic candidates toward potential regulatory approval.